https://www.selleckchem.com/products/GDC-0879.html
The primary efficacy outcome occurred in 4 patients (3.7%) taking warfarin and none taking edoxaban (risk difference, -0.0367; 95% confidence interval, -0.0720 to -0.0014; P.001 for noninferiority). The primary safety outcome occurred in 1 patient (0.9%) taking warfarin and 3 patients (2.8%) taking edoxaban (risk difference, 0.0183; 95% confidence interval, -0.0172 to 0.0539; P=.013 for noninferiority). Edoxaban is noninferior to warfarin for preventing thromboembolism and is potentially comparable for risk of major bleeding during
Like
Comment
Share
